Otonomy, Inc., a biopharmaceutical firm established in 2008 and headquartered in San Diego, California, concentrates on pioneering treatments for neurotological disorders throughout the United States. Its robust pipeline includes several programs: OTO-313, a sustained-release formulation of the N-methyl-D-aspartate receptor antagonist gacyclidine, currently in Phase II clinical trials for addressing tinnitus; and OTO-413, a sustained-exposure brain-derived neurotrophic factor, which is undergoing Phase IIa studies to mend cochlear synaptopathy and alleviate speech-in-noise hearing difficulties. The company is also advancing OTO-510, an otoprotectant designed to prevent hearing loss induced by cisplatin, along with OTO-825, a gene therapy aimed at congenital hearing loss. Additionally, OTO-6XX is being developed to stimulate hair cell repair and regeneration for severe hearing impairment. Otonomy holds licensing agreements with the University of California and DURECT Corporation, and has a strategic alliance with Applied Genetic Technologies Corporation focused on gene therapy solutions for congenital hearing loss.